Verve Therapeutics Inc   (VERV)
Other Ticker:  
Price: $12.0100 $0.22 1.866%
Day's High: $12.2799 Week Perf: 0.67 %
Day's Low: $ 11.38 30 Day Perf: -13.78 %
Volume (M): 1,407 52 Wk High: $ 24.69
Volume (M$): $ 16,898 52 Wk Avg: $16.61
Open: $11.78 52 Wk Low: $8.22

 Market Capitalization (Millions $) 759
 Shares Outstanding (Millions) 63
 Employees -
 Revenues (TTM) (Millions $) 8
 Net Income (TTM) (Millions $) -193
 Cash Flow (TTM) (Millions $) -199
 Capital Exp. (TTM) (Millions $) 12

Verve Therapeutics Inc
Verve Therapeutics Inc. is a biotechnology company founded in 2019, with headquarters in Cambridge, Massachusetts. The company is dedicated to developing gene-editing therapies for cardiovascular diseases.

Verve Therapeutics uses the latest advancements in the field of genetic engineering, like CRISPR/Cas9, to create therapeutics that will eliminate the genetic causes of heart diseases. The company is focused on developing therapies that can potentially reduce the risk of heart attacks and other related diseases by targeting the genetic drivers of these conditions.

The co-founders of Verve Therapeutics Inc are Sekar Kathiresan, MD, and Andrew Bellinger, MD, PhD, both prominent researchers in the field of genetics and cardiovascular diseases. Dr. Kathiresan previously founded two successful genetic medicine companies - Editas Medicine and Verve Therapeutics, while Dr. Bellinger was the former Director of Translational Medicine at Merck.

Verve Therapeutics Inc.'s primary target is coronary artery disease, which is the leading cause of death worldwide. Other diseases that often go hand-in-hand with coronary artery disease, such as high cholesterol, are also in the company's sights. Through groundbreaking research and development, Verve Therapeutics is hoping to address a significant gap in the market for cardiovascular disease treatments.

The company's mission is to eliminate the genetic risk of cardiovascular disease through in vivo gene editing with unparalleled expertise in cardiovascular disease genetics, delivery systems, and protein engineering. Verve Therapeutics develops a pipeline of products to protect and prevent heart disease through cutting-edge technology and the CRISPR gene editing system.

Overall, Verve Therapeutics Inc. is a promising biotech company with an ambitious goal of revolutionizing gene-editing therapies for cardiovascular diseases. The company's highly experienced and dedicated team is comprised of renowned researchers and scientists committed to bringing innovative treatments that can change the lives of people at risk of coronary artery disease.

   Company Address: 201 Brookline Avenue, Suite 601 Boston 2215 MA
   Company Phone Number: 603-0070   Stock Exchange / Ticker: NASDAQ VERV
   VERV is expected to report next financial results on March 01, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Conduit Pharmaceuticals Inc

Conduit Pharmaceuticals Inc. Records Operating Shortfall in Q3 2023 but Reveals Promising Financial Indicators

As the earnings cycle for the third quarter of 2023 unfolds, various industries are reporting their financial results. One notable sector is Major Pharmaceutical Preparations, with Conduit Pharmaceuticals Inc being among the corporations announcing its numbers. Despite the absence of realized products and services, the company reported an operating shortfall of $-1.069 million during the July to September 30, 2023 period. However, a closer look at the financials reveals positive indicators, including a significant increase in net profits compared to the previous year. This article aims to analyze and contextualize the financial results of Conduit Pharmaceuticals Inc.
Financial Performance and Stakeholder Expectations:
During the current reporting period, Conduit Pharmaceuticals Inc faced an operating shortfall of $-1.069 million. This unfavorable figure, suggesting a loss for the company, signals the need for additional revenue sources to be explored as soon as possible. However, despite the current financial challenges, stakeholders seem less concerned about the organization's operational excellence and recent developments.

Ayala Pharmaceuticals Inc

ADXS Surpasses Expectations with Strong Third Quarter Results, Drives Optimism in the Pharmaceutical Industry

In the Major Pharmaceutical Preparations industry, where large companies dominate the market, smaller players are making their presence felt with promising results. One such company worth noting is ADXS, which recently announced an operating loss of $-7.131 million for the third quarter of 2023?a significant improvement compared to the same period last year, when the loss was $-7.291 million.
ADXS's positive results come as welcome news, particularly given the lack of easier references in the industry. This performance has generated optimism among market observers, who are now eyeing ADXS as a potential investment opportunity. The company's relentless pursuit of diverse corporate strategies aimed at ensuring new revenue streams has further bolstered this confidence.

Anebulo Pharmaceuticals Inc

Anebulo Pharmaceuticals Inc Achieves Promising Improvement, Reporting Operating Loss of $-2.543678 Million in Q1 2024

Anebulo Pharmaceuticals Inc, a lesser-known player in the Major Pharmaceutical Preparations sector, recently published their financial numbers for the first quarter of 2024. In a positive surprise for investors and analysts, the company announced that it had realized an operating loss of -$2.543678 million, an improvement from the previous year's operating loss of -$2.612047 million.
What is particularly noteworthy about this improvement is the decrease in diminishing returns, from -$2.612 million in the first quarter of 2023 to -$2.481 million in the same period this year. This suggests that Anebulo Pharmaceuticals Inc is making progress towards becoming an exceptional company in the Healthcare sector.

Qualigen Therapeutics Inc

Lackluster revenue at the Qualigen Therapeutics Inc in the most recent fiscal period

Qualigen Therapeutics Inc stock has seen some fluctuations in recent trading days. However, over the last five trading days, the stock experienced a solid gain of 7.2%. This positive movement comes after a slight decline of -1.91% during the preceding month.
Investors may also note that Qualigen Therapeutics Inc stock is currently trading only 12.3% above its 52-week low. This suggests that the stock has not seen significant upward momentum in recent months.

Onconova Therapeutics Inc

A deficit of $-0.23 per Share at the Onconova Therapeutics Inc amid the fiscal third quarter of 2023

Onconova Therapeutics Inc (ONTX) has recently reported its fiscal third-quarter results for 2023, and the numbers are not looking promising for the biopharmaceutical company. The company's financials reveal a decrease in earnings per share (EPS) compared to the same quarter last year, as well as a surge in deficit from the previous quarter.
For the fiscal third quarter of 2023, ONTX reported a loss of $-0.23 per share, which is slightly better than the loss of $-0.26 per share reported a year ago. However, compared to the previous quarter, the deficit has increased from $-0.20 per share. This indicates a concerning trend of worsening financial performance for the company.


Verve Therapeutics Inc's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com